; non-grandfathered private health insurance plans have to cover PrEP for such individuals without cost-sharing effective January 2021. Updated United States Preventive Service Task Force guidance incorporating the new long-acting injectable PrEP drug is pending. (10) Joint guidance issued by the Department of Labor, the Department of Health and Human Services, and the Department of the Treasury on July 19, 2021, clarifies that ancillary services necessary to maintain the PrEP regime, including subsequent provider visits, clinical testing, and other services, is required to be covered by health insurers without cost-sharing. (11) Permanently expanding access to cost-free PrEP and ancillary services for all individuals, including individuals who do not have health insurance, through legislation, is a critical step towards eliminating HIV transmission. (12) Post-exposure prophylaxis (referred to in this section as PEP ) is a daily antiretroviral treatment which, when initiated promptly after a sexual or other exposure to blood or body fluids that are associated with a high risk of HIV transmission, is highly effective at preventing HIV transmission. (13) The Centers for Disease Control and Prevention recommends PEP for an individual who has experienced a high-risk exposure incident, provided that the individual tests HIV-negative, initiates such treatment not later than 72 hours after exposure, and continues the treatment for 28 days. (14) Despite PEP’s proven effectiveness in preventing HIV transmission after high-risk sexual exposures, including sexual assault, awareness of PEP is low among individuals who would benefit from the treatment. Studies suggest that awareness of PEP and of the importance of its prompt initiation is particularly low among young gay and bisexual men of color, transgender individuals, and women of all gender identities. (15) Adequate knowledge of guidelines issued by the Centers for Disease Control and Prevention for assessing indications for PEP and for initiating and sustaining PEP are